Cancer Research UK, MSD and Verastem to collaborate in immunotherapy drug trial
Cancer Research UK announced its first cross-company deal as part of its Experimental Cancer Medicine Centre Combinations Alliance. MSD, Verastem, and Cancer Research UK will trial a new combination of immunotherapy drugs in mesothelioma, non small cell lung and pancreatic cancers. September 30, 2016